Merck & Co., Inc. vs Pfizer Inc.: Strategic Comparison
Key Differences at a Glance
| Field | Merck & Co., Inc. | Pfizer Inc. |
|---|---|---|
| Founded Year | 1891 | 1849 |
| Revenue | $63.6B | $63.6B |
| Employees | 74,000 | 88,000 |
| Market Cap | $215.0B | $148.0B |
| HQ Country | United States | United States |
| Business Model | When Merck & Co. | Pfizer's ability to set premium pricing in the United States — where pharmaceutical pricing is largely unregulated compared to European reference pricing systems — is therefore central to overall profitability. |
Quick Answer
Merck leads in oncology (Keytruda's dominance), pipeline depth, and operating margin. Pfizer leads in vaccine technology (mRNA platform), breadth of therapeutic areas, and COVID-era revenue scale.
Quick Stats Comparison
| Metric | Merck & Co., Inc. | Pfizer Inc. |
|---|---|---|
| Revenue | $63.6B | $63.6B |
| Founded | 1891 | 1849 |
| Headquarters | Rahway, New Jersey | New York, New York |
| Market Cap | $215.0B | $148.0B |
| Employees | 74,000 | 88,000 |
Merck & Co., Inc. Revenue vs Pfizer Inc. Revenue — Year by Year
| Year | Merck & Co., Inc. | Pfizer Inc. | Leader |
|---|---|---|---|
| 2024 | $63.6B | $63.6B | Merck & Co., Inc. |
| 2023 | $60.1B | $58.5B | Merck & Co., Inc. |
| 2022 | $59.3B | $100.3B | Pfizer Inc. |
| 2021 | $48.7B | $81.3B | Pfizer Inc. |
| 2020 | $48.0B | $41.9B | Merck & Co., Inc. |
Merck & Co., Inc. Model
- Licensed pembrolizumab — the compound that would eventually become Keytruda — from Organon in 2009 for a modest upfront payment, the PD-1 pathway it targeted was considered a promising but scientifically crowded corner of immuno-oncology where Bristol Myers Squibb appeared to hold a decisive lead
- The pricing power underlying Keytruda's revenue is substantial and structurally embedded
- The competitive risk in vaccines is not from scientific rivals but from public health and pricing dynamics: government procurement decisions in large markets like China can shift billions of dollars of revenue with little commercial warning, as the 2023-2024 China pullback demonstrated
- Pricing pressure in the United States escalated in a structurally new way with the implementation of Medicare drug price negotiation provisions under the Inflation Reduction Act of 2022
- That antibody, identified through research conducted at Schering-Plough's Organon BioSciences subsidiary and subsequently licensed to Merck, would be developed through a decade of clinical investment into pembrolizumab — the compound that became Keytruda
Pfizer Inc. Model
- Pfizer's ability to set premium pricing in the United States — where pharmaceutical pricing is largely unregulated compared to European reference pricing systems — is therefore central to overall profitability
- The Inflation Reduction Act of 2022, which for the first time authorizes Medicare to negotiate drug prices directly with manufacturers, represents a structural change to this pricing model that Pfizer and its peers are still quantifying in terms of long-term revenue impact
- The Inflation Reduction Act's Medicare drug price negotiation provisions directly threaten pricing power on several Pfizer products, including Eliquis, which was among the first ten drugs selected for negotiation
- Internationally, reference pricing systems in Europe and government procurement leverage in emerging markets continue to compress net realized prices on Pfizer's portfolio
- Public scrutiny of pharmaceutical pricing practices — which intensified during the COVID-19 pandemic when Pfizer's commercial success from government-funded vaccine development became a political flashpoint — has sustained pressure on the company's pricing and communications strategy
- By formulating santonin with almond toffee to mask its bitter taste, Pfizer created one of the early examples of what we would today call a value-added pharmaceutical formulation — the active ingredient combined with delivery mechanisms designed to improve patient compliance
Company-Specific SWOT Notes
Merck & Co., Inc.
Keytruda's approval across more than 40 cancer indications and its more than 1,600 active clinical trials create a clinical evidence base and physician relationship network that represents the most formidable competitive position in the pharmaceutical industry
In non-small cell lung cancer — the prize indication given its prevalence and commercial scale — Merck pursued and won first-line approval with a companion diagnostic selecting patients with high PD-L1 expression, a strategy that created a diagnostically d
Keytruda's approximately $29.
The development of subcutaneous pembrolizumab — a formulation allowing injection in approximately five minutes versus 30-minute intravenous administration — could substantially reduce the commercial attractiveness of biosimilar IV pembrolizumab for both pa
The Inflation Reduction Act's Medicare drug price negotiation framework represents the most significant structural threat to Merck's near-term financial profile.
Pfizer Inc.
Pfizer operates more than 40 manufacturing facilities globally, producing small molecules, biologics, sterile injectables, and mRNA-based vaccines at industrial scale.
Pfizer's regulatory affairs organization has successfully navigated FDA and EMA drug approval processes for hundreds of drug products over more than seven decades, accumulating institutional knowledge about clinical trial design, data presentation requirements
Pfizer faces the expiration of intellectual property protection on products representing approximately $17-18 billion in annual revenues between 2025 and 2030, including Eliquis (generics in late 2020s), Ibrance (composition-of-matter patents expire 2027), and
The ADC technology platform acquired through Seagen positions Pfizer at the forefront of what many oncology experts consider the most promising drug modality for solid tumor treatment over the next decade.
The Inflation Reduction Act of 2022 authorizes the Centers for Medicare and Medicaid Services to directly negotiate prices for certain high-expenditure Medicare Part D drugs for the first time in the program's history.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Merck & Co., Inc. | Merck & Co., Inc. reports the larger revenue base ($63.6B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1891 vs 1849. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Merck & Co., Inc. | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Pfizer Inc. | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Merck & Co., Inc. | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Merck & Co., Inc. reports the larger revenue base ($63.6B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1891 vs 1849. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Merck & Co., Inc. or Pfizer Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Merck & Co., Inc. vs Pfizer Inc.
Is Merck & Co., Inc. better than Pfizer Inc.?
Merck's Keytruda franchise is the most valuable single drug asset in pharma. Pfizer has more diversified revenue but faces a patent cliff in the late 2020s.
Who earns more — Merck & Co., Inc. or Pfizer Inc.?
Merck & Co., Inc. earns more with $63.6B in annual revenue versus Pfizer Inc.'s $63.6B. Merck & Co., Inc. leads on total revenue based on latest verified figures.
Which company has higher revenue — Merck & Co., Inc. or Pfizer Inc.?
Merck & Co., Inc. reported $63.6B, while Pfizer Inc. reported $63.6B. The revenue leader is Merck & Co., Inc. based on latest verified figures.
Merck & Co., Inc. revenue vs Pfizer Inc. revenue — which is higher?
Merck & Co., Inc. revenue: $63.6B. Pfizer Inc. revenue: $63.6B. Merck & Co., Inc. has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Merck & Co., Inc. Annual Filings (10-K, 8-K)
- Merck & Co., Inc. Corporate Website
- Merck & Co., Inc. Annual Report 2024 - Revenue and Financial Data
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2024 - Revenue and Financial Data
Quick Answer
Merck leads in oncology (Keytruda's dominance), pipeline depth, and operating margin. Pfizer leads in vaccine technology (mRNA platform), breadth of therapeutic areas, and COVID-era revenue scale.
Verdict
Merck's Keytruda franchise is the most valuable single drug asset in pharma. Pfizer has more diversified revenue but faces a patent cliff in the late 2020s.